Counterparties stepping up before the numbers do: escalating committed demand the reported results don't yet show
The model's full reasoning — Q4 2022 call → NOWe need to determine if management describes a real escalation by paying counterparties that is already happening or committed, and that the reported results do not yet reflect it because its contribution is only beginning. Let's analyze the transcript. Chris Diorio says: "We delivered record revenue in both the fourth quarter and for the full year. We delivered sequential double-digit revenue growth in second, third, and fourth quarters. We delivered record adjusted EBITDA in the third and fourth quarters. We delivered our 75 billionth endpoint IC, another milestone on our journey to connect every item in our everyday world. And we have record backlog entering 2023. Our strong support for, and shipments to, enterprise end-users drove those results, despite persistent wafer and component shortfalls. As we look into 2023, we see significant end-user opportunities for our platform, and we expect those opportunities to pay further dividends in the form of continued strong endpoint IC volume growth." He mentions record backlog, but that's about supply constraints. He says "we see significant end-user opportunities" - that's future, not necessarily committed. Later: "Starting with endpoint ICs, 2022 demand held strong, with program expansions and new programs more-than-offsetting retail inventory headwinds." That's about demand, but not necessarily a step-up beyond prior level. He says: "The bulk of that growth is rooted in our platform focus on supply chain and logistics package tracking as well as retail self-checkout and loss prevention." That's about focus. On wafer supply: "we are seeing improved supply. As anticipated, our inlay partners layered on additional bookings as our wafer visibility improved, creating record year-end backlog." That indicates partners are booking more, but that's about supply. He says: "With that improved supply, we can and will ramp shipments into that strong demand. That said, our shipment volumes will remain constrained at least into second-half 2023 to wafer-delivery timing and teething issues as we ramp our expanded 300 millimeter post-processing to volume production." So they are constrained.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| GVP | GSE Systems, Inc. | Q1 2023 | 2023-05-15 | D |
| OEC | Orion Engineered Carbons S.A. | Q4 2022 | 2023-02-17 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| VNRX | VolitionRx Limited | Q1 2022 | 2022-05-12 | F |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| KOP | Koppers Holdings Inc. | Q2 2018 | 2018-08-12 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
KOP · Q2 2018 → YESThe question is: Does management describe that counterparties (customers etc.) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that reported results do not yet meaningfully reflect...**NO** The transcript does not describe any counterparties (customers, clients, partners, etc.) currently stepping up their commitment to a distinctly higher level of engagement beyond prior patterns in a way that is already occurring or committed now, with the reported results lagging because most of the benefit is still ahead. The closest item is the major box store converting its ground-contact treated wood program to Koppers’ patented MicroPro technology, planned for late fall with “little effect on the balance of 2018” and a “nice boost heading into 2019.
SCPH · Q3 2023 → YESThe question is: Does management describe that counterparties who pay the company are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully ...YES The transcript shows management describing a clear escalation in payer commitments: a new unrestricted-access agreement with the largest closed IDN (over 8 million lives, fixed copay) and preferred formulary status with a major government retiree payer (adding 1.1 million lives). They explicitly note that direct IDN purchases were not meaningful in Q3 but will be “a meaningful part of our business” moving forward, especially in 2024, and that the new payer decisions “could positively impact FUROSCIX co-pays as early as the fourth quarter.
GFS · Q3 2021 → YESThe question is: Does management describe that counterparties (customers) are CURRENTLY STEPPING UP their commitment beyond prior levels, AND that the reported results do not yet meaningfully reflect ...**YES** Management describes counterparties (customers) stepping up their commitment through new and expanded long-term agreements (LTAs) and prepayments/access fees, which have grown since the roadshow (from ~$2.5B to north of $3B, with additional $500M+ added post-roadshow) and now exceed $20B in forward revenues. This is framed as real escalation in committed business, with customers signing more agreements and prepaying for future capacity. The reported Q3 results ($1.7B revenue, $0.07 adjusted EPS) and Q4 guidance ($1.